SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

OG-L002

Cat. No.:	HY-19333
CAS No.:	1357302-64-7
Molecular Formula:	$C_{15}H_{15}NO$
Molecular Weight:	225.29
Target:	Histone Demethylase; Monoamine Oxidase; HSV
Pathway:	Epigenetics; Neuronal Signaling; Anti-infection
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (443.87 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	4.4387 mL	22.1936 mL	44.3872 mL
	5 mM	0.8877 mL	4.4387 mL	8.8774 mL
	10 mM	0.4439 mL	2.2194 mL	4.4387 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1.67 mg/mL (7.41 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1.67 mg/mL (7.41 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1.67 mg/mL (7.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

OG-L002 is a potent and highly selective LSD1 inhibitor with an IC_{50} of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC_{50}s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes[1].

IC_{50} & Target

IC50: 0.02 μM (LSD1), 1.38 μM (MAO-A), 0.72 μM (MAO-B), HSV IE[1]

In Vitro	OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC_{50} (IC_{50}: ~10 μM in HeLa cells; IC_{50}: ~3 μM in HFF cells) relative to the control MAOI TCP (IC_{50}: ~1 mM)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-week-old BALB/c female mice[1]
Dosage:	6, 20, 40 mg/kg
Administration:	Intraperitoneal; daily; for 7 days
Result:	Reduced the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection.

CUSTOMER VALIDATION

- Patent. US20180263995A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Liang Y, et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio. 2013 Feb 5;4(1):e00558-12.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA